Autopsy report · NCT00594308
In-Vivo Activated T-Cell Depletion to Prevent GVHD
Cause of deathFutility
“Treatment ineffective”
Life of this trial
- Registered 3 months after it had already started.
- 10 participants enrolled.
- Results were posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Na
- Sponsor
- Indiana University
- Sponsor type
- University, hospital or other
- Conditions
- Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Lymphocytic Leukemia; Myelodysplasia; Lymphoma, Non-Hodgkin's
- Interventions
- Cyclophosphamide; Fludarabine; Cyclosporine; Mycophenolate mofetil; Basiliximab
- Participants
- 10
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery
“have been published new studies that it showed the ineffectiveness of the treatments proposed in this study.” - Efficacy of the Infusion of Donor Plasma in COVID-19 Infection
“Lack of efficacy of treatment tested” - Dasatinib in Polycythemia Vera
“This study was terminated due to lack of efficacy.” - A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
“This study was terminated due to a lack of efficacy.” - Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
“Lack of efficacy of the drug; no safety concern”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.